Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties

James A. McCubrey; Akshaya K. Meher; Shaw M. Akula; Stephen L. Abrams; Linda S. Steelman; Michelle M. LaHair; Richard A. Franklin; Alberto M. Martelli; Stefano Ratti; Lucio Cocco; Fulvio Barbaro; Przemys&#x142;aw Duda; Agnieszka Gizak

doi:doi:10.18632/aging.204038

← Back

Research Paper Volume 14, Issue 8 pp 3365—3386

Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties

Figure 9. Effects of pLXSN and WT-TP53 on the colony formation in soft agar in the presence of 5-Fluorouracil. The effects of pLXSN and WT-TP53 on the colony formation in soft agar were examined. Red squares = MIA-PaCa-2 + pLXSN cells, blue circles = MIA-PaCa-2 + WT-TP53 cells. IC₅₀ is indicated with a purple dotted line and IC₂₅ is indicated with a green dotted line. IC₂₅ is a term to indicate inhibition of colony formation at 25%. These experiments were repeated performed and similar results were observed. The colonies for each cell line were normalized to untreated cells so that the results from the MIA-PaCa-2 + pLXSN and MIA-PaCa-2 + WT-TP53 could be compared. ^**P < 0.005.